$ORHB: An Advanced Surgical SaaS Company Capitalizing on

New Post Public Reply Private Reply Replies (0) Message Board
SpotlightGrowth1
518
$ORHB: An Advanced Surgical SaaS Company Capitalizing on the Digitalization of Health Care


For Full Article Visit: http://spotlightgrowth.com/index.php/2018/09/...alth-care/

ORHub, Inc. is a Laguna Beach, California-based advanced surgical software-as-a-service (SaaS) solutions provider. The company also has offices in Tempe, Arizona; Newport Beach, California; Bellevue, Washington; and Jacksonville, Florida.

Born from the “Microsoft for Start-Ups” program and hosted on their Azure cloud platform, ORHub, Inc.’s suite of products are hosted with a top-tier cloud network provider. This helps ensure the company can focus on solving the problems that plague the business of surgery.

The HIPAA-compliant platform allows health care providers to digitally capture accurate surgical records and analyze its data in real-time. “ORHub’s cloud-based software solution captures information before, during and after surgery to fill a void in the current surgical information infrastructure and provides the first platform to capture and measure the surgical process on any web-enabled device,” according to the company’s description.

The company’s surgical resource management (SRM) application is then able to automatically creates a live surgical case receipt that tracks each element of a surgical case including type of procedure, indication, and materials used that is verified by the physician and nurse. This means the report will capture everything from implants, biologocis, surgical procedures used to product’s manufacturer, utilization, and other information.

This is not only extremely convenient, but it also solves a major problem and inefficiency within the current health care climate. Health care providers are often burdened with massive amounts of paperwork and data entry, which ultimately takes time away from seeing additional patients. With the automatic live surgical records being generated, providers will see reduced costs and improved workflow, which can lead to greater quality of care for patients.

Through September 2018, ORHub, Inc. has collected data from over 5,700 surgical cases so far this year alone. The company also noted a greater than 80% physician adoption rate.

ORHB: Recent News & Developments
September 2018

14th– ORHub announced that it had appointed Dr. Burak Ozgur to its Medical Advisory Board. The award-winning neurosurgeon is considered to be among the best in the U.S. specializing in minimally invasive spine neurosurgeries.

“What’s exciting about ORHub is that finally there is a product that aims to streamline the practical aspects of surgical equipment, implants and tools for the hospital OR system while helping to translate that value into surgical outcomes and efficiency,” detailed Dr. Ozgur.

August 2018

27th– The company announced that it has expanded its core platform capabilities to include new features focused on helping improve reimbursement for providers. ORHub’s SMART Scanning technology helps free up nurses from manually inputting the data. Furthermore, this allows for more accurate reimbursement.

“Our internal research indicates that our taxonomy approach to optimizing reimbursement and our proprietary scanning and parsing technology resolve chronic surgical problems by uncovering missed revenue opportunities and capturing time savings that could result in millions of dollars of efficiencies that can be recovered per hospital. We are excited to scale our modules to market in the next quarter and will continue to work with our clients to provide breakthrough technological solutions that align with value-based healthcare,” detailed Colt Melby, CEO of ORHub.

20th– ORHub announces plans to expand data analytics platform in response to U.S. Food & Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) initiatives in Electronic Health Records (EHR).

Back in June 2018, the FDA announced that all new trials of medical devices must provide Healthcare Economic Information before receiving approval. Furthermore, CMS announced a set of reforms to help improve care quality while reducing burden from paperwork.

15th– ORHub announced that it had filed a U.S. patent for an augmented reality-enabled feature for Electronic Health Records. Specifically, the patent is for protection of using “3D Avatars for Electronic Medical Records.”

“Following our launch and implementation of our cloud-based SaaS Surgical Resource Management (SRM) platform, this patent filing further propels us along our development journey to extend beyond manual data capture in the surgical environment utilizing innovative new technology,” said Colt Melby, Chief Executive Officer of ORHub. “ORHub is committed to bringing transformative surgical economics for our rapidly growing number of providers to break through current challenges that EHR systems face.”

8th– ORHub announced mid-year updates, which included the company’s continuing efforts evolving from product innovation into a sales and marketing focus. The company announced that it had completed data analytics for 5,700 surgical procedures so far in 2018.

ORHub, Inc. also completed its uplisting to the OTCQB Venture Market, which provides greater transparency and confidence for investors.

2018 Milestones Year-to-Date

Upgraded to the OTCQB Venture Market
Powered data analytics for over 5,700 surgical cases to date
Developed three new modules that will move to market by calendar Q4 of 2018
Strengthened senior management team with the appointment of Barney Monte as Interim Chief Financial Officer
Strengthened the Board of Directors with the appointment of Stephen Cochennet as an Independent Director and Chairman of the Audit Committee
Outsourced technology programmers to a third party, helping reduce headcount by nearly 70% as we normalize operations and scale to market
Expanded indications from spine into cardiovascular and neurological surgical cases
Management & Advisors
Colt Melby, CEO

Mr. Melby was appointed Chairman and CEO of the company after the ORHub Asset Purchase. He was an initial Member of ORHub, LLC in November 2015 and served as its CEO. He has had a 30+ year career as a senior level executive in both public and private companies. Mr. Melby is an active entrepreneur and investor, taking officer positions when needed. His focus is on high-growth companies, recently in digital health and regenerative medicine.

Since December 2015, Mr. Melby has been an independent Director on the Board of News Beat Social (NBS), a company that is in the process of a Reg A plus IPO. Prior to ORHub and the Company, between 2008 and 2014, Mr. Melby served as Chairman of the Board at CUI Global, Inc. a publicly traded holding company that develops and commercializes Innovative Industrial and Power Technologies (Nasdaq:CUI). Between 2012 and 2014, Mr. Melby also served as Vice Chairman of the Board at Quest Resource Holding Corp (Nasdaq:QRHC) and was the CEO of Earth911 (the predecessor company to QRHC). Previously, Mr. Melby financed the acquisition of Smith & Wesson by a public company. He subsequently served as President and Chief Operating Officer of publicly held Smith & Wesson Holding Corporation (NASDAQ:SWHC) from September 2002 to December 2003 and served on the Board of SWHC between 2001-2008. Mr. Melby has also served in a number of positions within the aerospace industry, most recently with Metal Form, Inc., a privately held aerospace manufacturing company, where he served as President and Chief Executive Officer from 1987 to September of 1999.

William Dobkin, MD (Co-Founder and Advisor)

William Dobkin, M.D., along with Mr. Wiggins, was a founder and visionary for the ORHub software system. In November 2015, they formed iDataMD, LLC to pursue this vision. Dr. Dobkin’s primary vocation since 1985 has been the private practice of Neurosurgery. His current specialty is treating complex problems associated with the spine. He has been involved with roughly 15,000 surgeries involving the brain and the spine. Along with Dr. William House, one of the giants of American medicine, Dr. Dobkin previously specialized in surgical treatment of acoustic neuromas and was blessed to operate on hundreds of patients from around the world. Dr. Dobkin has degrees in Chemistry and Biology and earned his medical degree at the University of Southern California. Thereafter, he spent 6 years in post-graduate training at the Los Angeles County – USC medical center.

Richard Lee, MD (Advisor)

Richard Lee, M.D. is a spinal surgeon practicing in Orange County, CA. Dr. Lee is the Co-director of the Spine service at the nationally acclaimed, high volume surgical hospital, Hoag Orthopedic Institute (HOI). He has been with HOI since 2010 and serves or has served in various positions including the medical executive committee, quality assurance committee, clinical leadership committee, infection control committee, and spine committee. Dr. Lee has also served as a consultant to major corporations including Stryker, Johnson & Johnson, and Globus Medical, giving him insight into the demands challenging the biomedical industry. Dr. Lee’s professional career began as a researcher in molecular biology at the University of California Berkeley, Lawrence Berkeley National Laboratory, and NASA. After receiving a BA degree in Molecular Biology with Honors (1998) from UC Berkeley and a Doctorate in Medicine with distinction (2003) from Albert Einstein College of Medicine, he went on to the Yale School of Medicine for General Surgery internship (2003-2004) and Orthopedic Surgery Residency training (2004-2008) and to Harvard Medical School for Spinal Surgery fellowship training (2008-2009).

Overall, ORHub, Inc. continues to make great decisions in order to gain as much exposure to the digitalization of the healthcare sector. The all-star management team has an extremely successful history of running public companies and developing technologies. Backed by a heavy-hitting Medical Advisory Board, the Company has an effective leadership to truly carry out its objective to transform the business of surgery. The company has already completed 5,700 data collections on surgeries this year, showing that there are still massive amounts of growth still to be had. As the Company transitions into the sales and marketing aspect of operations, the revenue growth engine is just getting fired up.

Disclaimer:

Spotlight Growth is compensated, either directly or via a third party, to provide investor relations services for its clients. Spotlight Growth creates exposure for companies through a customized marketing strategy, including design of promotional material, the drafting and editing of press releases and media placement.

All information on featured companies is provided by the companies profiled, or is available from public sources. Spotlight Growth and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The information contained herein is based on external sources that Spotlight Growth believes to be reliable, but its accuracy is not guaranteed. Spotlight Growth may create reports and content that has been compensated by a company or third-parties, or for purposes of self-marketing. Spotlight Growth was compensated two thousand dollars cash by a third party for the creation and dissemination of this content.

This material does not represent an investment solicitation. Certain statements contained herein constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may include, without limitation, statements with respect to the Company’s plans and objectives, projections, expectations and intentions. These forward-looking statements are based on current expectations, estimates and projections about the Company’s industry, management’s beliefs and certain assumptions made by management.

The above communication, the attachments and external Internet links provided are intended for informational purposes only and are not to be interpreted by the recipient as a solicitation to participate in securities offerings. Investments referenced may not be suitable for all investors and may not be permissible in certain jurisdictions.

Spotlight Growth and its affiliates, officers, directors, and employees may have bought or sold or may buy or sell shares in the companies discussed herein, which may be acquired prior, during or after the publication of these marketing materials. Spotlight Growth, its affiliates, officers, directors, and employees may sell the stock of said companies at any time and may profit in the event those shares rise in value. For more information on our disclosures, please visit: http://spotlightgrowth.com/index.php/disclosures/

ORHUB, Inc. (ORHB) Stock Research Links

ORHB Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ris-Rez May Set New Standard in Relapsed SCLC

Updated Category News Views 5

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Continue Reading
Trial Disappointment: No Significant Gains in NSCLC

Updated Category News Views 7

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Continue Reading
Tam-Peli Steps Up in SCLC Battle: Trial Insights

Updated Category News Views 5

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

Continue Reading
PwC US and India Unite for Global Consultancy Powerhouse

Updated Category News Views 6

Rearranging the Consultancy Chessboard Piling onto the game of consultancy realignments, PwC just made a move reminiscent of playing strategy poker. They're tossing together PwC US and PwC India's advisory capabilities for a new joint venture. It’s like pushing two puzzle pieces to make a single colorful picture that stretches from the U.S. all the way to the...

Continue Reading
UWM Faces Class Action Deadline: Key Insights for Investors

Updated Category News Views 2

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Continue Reading
Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Updated Category News Views 1

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...

Continue Reading
MRI Surveillance Gains Ground in Lung Cancer Care

Updated Category News Views 3

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Continue Reading
PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

Updated Category News Views 4

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

Continue Reading
First-Time Homeowners: Unseen Pitfalls of Insurance

Updated Category News Views 2

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

Continue Reading
GORGIE Unleashes Berry Burst: Target's New Drink Star

Updated Category News Views 2

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

Continue Reading

Top 5 Most Recently Viewed Articles

Thor Equities Sells Amazon Distribution Center for $157M

Updated Category News Views 191

Thor Equities Group Successfully Transacts Major Sale Thor Equities Group, recognized as a leader in urban real estate development and management, has successfully concluded the sale of a significant industrial property. The property, located at 280 Richards Street in Brooklyn, was sold for an impressive $157 million. Details of the 280 Richards Street Property This...

Continue Reading
Exploring the Dynamics of Cloud Object Storage Growth and Demand

Updated Category News Views 169

Understanding Cloud Object Storage Market Evolution The growth of the Cloud Object Storage Market is driven by the exponential rise in unstructured data, increasing adoption of cloud-based services, and the need for scalable, cost-effective storage solutions across industries. Enterprises are rapidly shifting toward hybrid and multi-cloud strategies, boosting demand for...

Continue Reading
Danone's Strategic Acquisition of Kate Farms to Drive Growth

Updated Category News Views 341

Danone Strengthens U.S. Nutrition Offerings with Kate Farms Purchase In a significant move for its health-focused division, Danone has officially finalized the acquisition of a majority stake in Kate Farms. This acquisition positions Danone as a key player in the specialized nutrition market by integrating Kate Farms’ lineup of plant-based, organic nutrition products....

Continue Reading
GSK plc Faces Class Action Over Zantac and Investor Rights

Updated Category News Views 175

Rosen Law Firm Encourages GSK plc Investors to Take Action Rosen Law Firm, renowned for advocating investor rights, is reaching out to shareholders of GSK plc (NYSE: GSK). The firm has been alerted to a class action alleging that GSK misrepresented crucial information regarding its business operations during the class period from February 5, 2020, to August 14, 2022....

Continue Reading
Alibaba's Recent Stock Surge Driven by Cloud Innovation

Updated Category News Views 181

Alibaba Group Holding Ltd's Stock Performance Alibaba Group Holding Ltd (NASDAQ: BABA) recently saw its shares soar by an impressive 18.5% on the Hong Kong Stock Exchange. This spike occurred amid high expectations following a solid quarterly performance from the company’s cloud computing division alongside the launch of a new artificial intelligence chip. Investors are...

Continue Reading